FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105193766> ?p ?o ?g. }

• W2105193766 endingPage "292" @default.
• W2105193766 startingPage "284" @default.
• W2105193766 abstract "Background Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients. Methods In this placebo-controlled, randomised, double-blind, multicentre phase 3 study, we enrolled adult patients recipient-seropositive or donor-seropositive for cytomegalovirus who had undergone allogeneic stem-cell transplantation. Patients were recruited from 90 centres in Canada, Europe, and the USA. After engraftment, patients were stratified by recipient cytomegalovirus serostatus and conditioning regimen (myeloablative or reduced-intensity) and assigned (2:1) by masked computer-generated randomisation sequence to receive maribavir 100 mg twice daily or placebo for up to 12 weeks, with weekly blood cytomegalovirus surveillance. If the virus was detected, administration of study drug was stopped and pre-emptive anticytomegalovirus treatment started. The primary endpoint was cytomegalovirus disease within 6 months of transplantation. Analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, NCT00411645. Findings Between December, 2006, and May, 2008, 681 patients were enrolled and assigned to receive maribavir (454) or placebo (227). The incidence of cytomegalovirus disease within 6 months was 20 of 454 (4%) for the maribavir group and 11 of 227 (5%) for the placebo group (OR 0·90; 95% CI 0·42–1·92). During the 100 days following transplantation, cytomegalovirus infection rates as measured by pp65 antigenaemia were lower in the maribavir group (26·4%) than in the placebo group (34·8%; OR 0·67; 0·47–0·95), but not when measured by plasma cytomegalovirus DNA PCR (27·8% vs 30·4%; OR 0·88; 0·62–1·25), nor by initiation of treatment against cytomegalovirus (30·6% vs 37·4%; OR 0·73, 0·52–1·03). Maribavir was well tolerated: most adverse events, including incident acute graft-versus-host disease and neutropenia, affected both groups equally, except for taste disturbance (15% maribavir, 6% placebo). Interpretation Compared with placebo, maribavir prophylaxis did not prevent cytomegalovirus disease when started after engraftment. Cytomegalovirus disease as a primary endpoint might not be sufficient to show improvements in cytomegalovirus prevention in recipients of allogeneic stem-cell transplants in the setting of pre-emptive antiviral treatment. Clinical and virological composite endpoints should be used in future trials. Funding ViroPharma Incorporated." @default.
• W2105193766 created "2016-06-24" @default.
• W2105193766 creator A5004106499 @default.
• W2105193766 creator A5011325960 @default.
• W2105193766 creator A5014346242 @default.
• W2105193766 creator A5016360607 @default.
• W2105193766 creator A5017514499 @default.
• W2105193766 creator A5029149386 @default.
• W2105193766 creator A5037473051 @default.
• W2105193766 creator A5038572943 @default.
• W2105193766 creator A5059865319 @default.
• W2105193766 creator A5065590894 @default.
• W2105193766 creator A5071055678 @default.
• W2105193766 creator A5075131927 @default.
• W2105193766 creator A5079082437 @default.
• W2105193766 creator A5079087824 @default.
• W2105193766 creator A5086668079 @default.
• W2105193766 creator A5088776058 @default.
• W2105193766 date "2011-04-01" @default.
• W2105193766 modified "2023-10-10" @default.
• W2105193766 title "Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial" @default.
• W2105193766 cites W1564109452 @default.
• W2105193766 cites W1955863325 @default.
• W2105193766 cites W1973646541 @default.
• W2105193766 cites W1982044703 @default.
• W2105193766 cites W1989307686 @default.
• W2105193766 cites W1989700483 @default.
• W2105193766 cites W1992168621 @default.
• W2105193766 cites W2008397578 @default.
• W2105193766 cites W2011660868 @default.
• W2105193766 cites W2030678166 @default.
• W2105193766 cites W2034051419 @default.
• W2105193766 cites W2034740985 @default.
• W2105193766 cites W2039673714 @default.
• W2105193766 cites W2046834426 @default.
• W2105193766 cites W2063945161 @default.
• W2105193766 cites W2064796142 @default.
• W2105193766 cites W2073770511 @default.
• W2105193766 cites W2078445214 @default.
• W2105193766 cites W2091704657 @default.
• W2105193766 cites W2096233660 @default.
• W2105193766 cites W2096682430 @default.
• W2105193766 cites W2106227497 @default.
• W2105193766 cites W2110927467 @default.
• W2105193766 cites W2112067138 @default.
• W2105193766 cites W2112300621 @default.
• W2105193766 cites W2117471032 @default.
• W2105193766 cites W2129282759 @default.
• W2105193766 cites W2148901424 @default.
• W2105193766 cites W4229668175 @default.
• W2105193766 doi "https://doi.org/10.1016/s1473-3099(11)70024-x" @default.
• W2105193766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21414843" @default.
• W2105193766 hasPublicationYear "2011" @default.
• W2105193766 type Work @default.
• W2105193766 sameAs 2105193766 @default.
• W2105193766 citedByCount "302" @default.
• W2105193766 countsByYear W21051937662012 @default.
• W2105193766 countsByYear W21051937662013 @default.
• W2105193766 countsByYear W21051937662014 @default.
• W2105193766 countsByYear W21051937662015 @default.
• W2105193766 countsByYear W21051937662016 @default.
• W2105193766 countsByYear W21051937662017 @default.
• W2105193766 countsByYear W21051937662018 @default.
• W2105193766 countsByYear W21051937662019 @default.
• W2105193766 countsByYear W21051937662020 @default.
• W2105193766 countsByYear W21051937662021 @default.
• W2105193766 countsByYear W21051937662022 @default.
• W2105193766 countsByYear W21051937662023 @default.
• W2105193766 crossrefType "journal-article" @default.
• W2105193766 hasAuthorship W2105193766A5004106499 @default.
• W2105193766 hasAuthorship W2105193766A5011325960 @default.
• W2105193766 hasAuthorship W2105193766A5014346242 @default.
• W2105193766 hasAuthorship W2105193766A5016360607 @default.
• W2105193766 hasAuthorship W2105193766A5017514499 @default.
• W2105193766 hasAuthorship W2105193766A5029149386 @default.
• W2105193766 hasAuthorship W2105193766A5037473051 @default.
• W2105193766 hasAuthorship W2105193766A5038572943 @default.
• W2105193766 hasAuthorship W2105193766A5059865319 @default.
• W2105193766 hasAuthorship W2105193766A5065590894 @default.
• W2105193766 hasAuthorship W2105193766A5071055678 @default.
• W2105193766 hasAuthorship W2105193766A5075131927 @default.
• W2105193766 hasAuthorship W2105193766A5079082437 @default.
• W2105193766 hasAuthorship W2105193766A5079087824 @default.
• W2105193766 hasAuthorship W2105193766A5086668079 @default.
• W2105193766 hasAuthorship W2105193766A5088776058 @default.
• W2105193766 hasConcept C126322002 @default.
• W2105193766 hasConcept C141071460 @default.
• W2105193766 hasConcept C142462285 @default.
• W2105193766 hasConcept C142724271 @default.
• W2105193766 hasConcept C197934379 @default.
• W2105193766 hasConcept C203014093 @default.
• W2105193766 hasConcept C203092338 @default.
• W2105193766 hasConcept C204787440 @default.
• W2105193766 hasConcept C2522874641 @default.
• W2105193766 hasConcept C27081682 @default.
• W2105193766 hasConcept C2776409557 @default.
• W2105193766 hasConcept C2776535787 @default.
• W2105193766 hasConcept C2777732132 @default.

• next